Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2036-01-16 | Direct | 60,000 |
Reported balance
After 2026-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2: The options vest 100% on December 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest 100% on December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2026 Filed Jan 21, 2026 21:49 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000036 · form4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 18:21 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,500 | $3.55 | $19,514.00 |
DisclosureSEC source: 0001133416-25-000081 · form4a.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,269 Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 18:19 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,500 | $3.55 | $19,514.00 |
DisclosureSEC source: 0001133416-25-000080 · form4a.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,269 Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 16:29 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,500 | $3.55 | $19,514.00 |
DisclosureSEC source: 0001133416-25-000075 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,269 Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 14:38 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.90 | $14,495.00 |
DisclosureSEC source: 0001133416-25-000033 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,769 Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:04 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000010 · form4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-01-23 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2025. Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 13:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 10,000 | $0.81 | $8,134.00 |
DisclosureSEC source: 0001133416-24-000062 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,769 Read SEC document |
| October 17, 2024 Filed Oct 17, 2024 20:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,300 | $2.64 | $3,432.00 |
DisclosureSEC source: 0001133416-24-000058 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,769 Read SEC document |
| October 16, 2024 Filed Oct 16, 2024 20:12 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.70 | $13,500.00 |
DisclosureSEC source: 0001133416-24-000056 · form4.xml · nonDerivative · entry 2 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 80,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 16, 2024 Filed Oct 16, 2024 20:12 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.70 | $13,500.00 |
DisclosureSEC source: 0001133416-24-000056 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,469 Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 17:55 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,500 | $2.38 | $5,949.75 |
DisclosureSEC source: 0001133416-24-000044 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,469 Read SEC document |
| April 22, 2024 Filed Apr 22, 2024 20:04 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,500 | $2.98 | $7,450.00 |
DisclosureSEC source: 0001133416-24-000038 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,969 Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 20:42 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-24-000036 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · IRA Disclosed balance after: 18,063 Read SEC document |
| January 24, 2024 Filed Feb 7, 2024 21:47 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-24-000016 · form4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-24 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2024. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:42 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-23-000022 · form4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-01-26 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2023. Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 13:47 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 10,000 | $1.41 | $14,100.00 |
DisclosureSEC source: 0001133416-22-000093 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 75,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 19, 2022 Filed May 20, 2022 11:30 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $1.33 | $6,649.50 |
DisclosureSEC source: 0001133416-22-000063 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 65,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 18, 2022 Filed Apr 18, 2022 19:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $1.71 | $8,550.00 |
DisclosureSEC source: 0001133416-22-000057 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 60,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 21:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-22-000022 · form4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-24 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2022. Read SEC document |
| January 19, 2022 Filed Jan 19, 2022 16:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $1.96 | $9,806.00 |
DisclosureSEC source: 0001133416-22-000008 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 50,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 19, 2022 Filed Jan 19, 2022 16:18 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $1.96 | $9,806.00 |
DisclosureSEC source: 0001133416-22-000010 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 55,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 21:34 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.28 | $11,400.00 |
DisclosureSEC source: 0001133416-21-000027 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 50,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 19:09 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.34 | $11,700.00 |
DisclosureSEC source: 0001133416-21-000023 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 45,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 06, 2021 Filed Dec 15, 2021 21:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.28 | $11,400.00 |
DisclosureSEC source: 0001133416-21-000025 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 50,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 16:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,000 | $3.17 | $6,340.00 |
DisclosureSEC source: 0001133416-21-000017 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 40,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 21, 2021 Filed Oct 21, 2021 16:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,000 | $3.19 | $6,380.00 |
DisclosureSEC source: 0001133416-21-000013 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 38,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 19, 2021 Filed Oct 19, 2021 18:14 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 3,000 | $3.37 | $10,106.70 |
DisclosureSEC source: 0001133416-21-000011 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC Disclosed balance after: 36,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 23, 2021 Filed Sep 23, 2021 20:14 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 3,000 | $3.88 | $11,631.00 |
DisclosureSEC source: 0001140361-21-032248 · form4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC Disclosed balance after: 33,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 13:00 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.04 | $10,200.00 |
DisclosureSEC source: 0000899243-21-015010 · doc4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC Disclosed balance after: 30,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013818 · doc4.xml · derivative · entry 2 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013818 · doc4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such options vest 100% on March 31, 2022. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 12:00 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 5,000 | $2.57 | $12,848.00 |
DisclosureSEC source: 0000899243-20-024607 · doc4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC Disclosed balance after: 25,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 12:30 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 6,000 | $1.64 | $9,844.20 |
DisclosureSEC source: 0000899243-20-009061 · doc4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC Disclosed balance after: 20,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-20-001121 · doc4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-01-09 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2020. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 15:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 3,000 | $3.36 | $10,075.80 |
DisclosureSEC source: 0000899243-19-027471 · doc4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings, LLC Disclosed balance after: 14,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 17:30 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,290 | $3.71 | $4,785.90 |
DisclosureSEC source: 0000899243-19-023102 · doc4.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company wholly-owned by Freeman Global Holdings, LLC Disclosed balance after: 11,000 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were purchased in multiple transactions at prices ranging from $3.705 to $3.713 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by the Reporting Person at each separate price on each date of purchase. F2 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 25,700 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000035 · edgar.xml · derivative · entry 5 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company wholly-owned by Freeman Global Holdings, LLC Disclosed balance after: 25,700 Underlying: Common Stock · 1,928 shares Expires 2026-05-31 F2 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F2 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 4,753 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000035 · edgar.xml · derivative · entry 4 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,753 Underlying: Common Stock · 356 shares Expires 2026-05-31 F2 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F2 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,426 | $4.28 | $6,103.28 |
DisclosureSEC source: 0001179022-19-000035 · edgar.xml · nonDerivative · entry 2 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,469 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 7,710 | $4.28 | $32,998.80 |
DisclosureSEC source: 0001179022-19-000035 · edgar.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company wholly-owned by Freeman Global Holdings, LLC Disclosed balance after: 9,710 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 05, 2019 Filed Apr 8, 2019 20:30 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 500 | $4.73 | $2,365.00 |
DisclosureSEC source: 0001179022-19-000028 · edgar.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company wholly-owned by Freeman Global Holdings, LLC Disclosed balance after: 2,000 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,500 | $4.29 | $6,427.50 |
DisclosureSEC source: 0001179022-19-000025 · edgar.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By a limited liability company wholly-owned by Freeman Global Holdings, LLC Disclosed balance after: 1,500 F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000013 · edgar.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The options vest 100% on January 16, 2020. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 13:57 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,000 | $4.10 | $8,191.00 |
DisclosureSEC source: 0001179022-18-000013 · edgar.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 16,000 F1 · balance_after: Includes 6,000 shares that the reporting person previously mistakenly reported as being held directly and which should have been reported as being held indirectly, by the reporting person's IRA. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 13:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,000 | $4.10 | $8,191.00 |
DisclosureSEC source: 0001179022-18-000012 · edgar.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 16,000 F1 · balance_after: Includes 6,000 shares that the reporting person previously mistakenly reported as being held directly and which should have been reported as being held indirectly, by the reporting person's IRA. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:12 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 46,875 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001179022-17-000079 · edgar.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common stock · 46,875 shares Expires 2027-12-14 F1 · derivative.exercise_date: The options vest 100% on December 14, 2018. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 19:26 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 400 | $1.64 | $657.32 |
DisclosureSEC source: 0001179022-17-000070 · edgar.xml · nonDerivative · entry 2 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,043 Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 19:26 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 8,000 | $1.63 | $13,004.80 |
DisclosureSEC source: 0001179022-17-000070 · edgar.xml · nonDerivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 8,000 Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 31,250 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001179022-16-000136 · edgar.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common stock · 31,250 shares Expires 2026-12-15 F1 · derivative.exercise_date: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.